ITEMS IN AFP WITH KEYWORD:
Aug 15, 2020 Issue
Colorectal Cancer Screening: BMJ Rapid Recommendation [Practice Guidelines]
Colorectal cancer (CRC) screening recommendations vary because the underlying evidence is low quality, with few screening methods evaluated by randomized trials. The BMJ/MAGIC Group performed a systematic review based on 15-year CRC risk models to compare screening options.
Mailed outreach significantly increases rates of colorectal cancer screening, with four tests needing to be mailed to screen one person.
The use of aspirin, NSAIDs, and oral anticoagulants has no clinically important effects on the positive predictive value of FIT in a screening population.
Key clinical questions and their evidence-based answers directly from the journal's content, written by and for family physicians.
Daily low-dose aspirin can be offered to patients older than 50 years for colon cancer prevention.
This meta-analysis provides high-quality evidence that ﬂexible sigmoidoscopy and fecal occult blood testing both reduce the risk of death from colorectal cancer. The study did not provide a clear answer regarding a superior screening modality, so the decision to choose one test over another should b...
Jul 1, 2019 Issue
mSEPT9 (Epi proColon) Blood Test for Colorectal Cancer Screening [Diagnostic Tests: What Physicians Need to Know]
Epi proColon is a blood test used for the detection of the methylated septin 9 (mSEPT9) gene. It is approved by the U.S. Food and Drug Administration for colorectal cancer screening in people at average risk who have declined first-line screening tests.
Over a 10-year period, the rates of detection of colorectal cancer (CRC) and advanced adenomas using FIT are similar to those seen in studies of screening colonoscopy. This does not prove that FIT reduces morbidity and mortality due to CRC as effectively as colonoscopy.
To support early identification and treatment, the American Cancer Society (ACS) has updated its 2008 guidance on counseling and referring patients at average risk of colorectal cancer (CRC) based on new evidence regarding screening options and the ever-changing risk of CRC.
FIT is more sensitive and specific than the older guaiac-based fecal occult blood tests (gFOBTs) when screening for colorectal cancer. We now know that it is also more acceptable to patients and increases uptake in a centrally administered screening program.